Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04811339 · ClinicalTrials.gov registry record · Phase 4
Studies of COVID-19 Patients Treated With Oral Bismuth Subsalicylate (Pepto-Bismol)
A Phase 4 study, sponsored by University of Cincinnati.
- Completed
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
NCT04811339 is a Phase 4 study that has completed, run by University of Cincinnati. The registered enrollment target is 60 participants.
The verdict
NCT04811339, a Phase 4 study, has completed, sponsored by University of Cincinnati.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
Study Summary
The Center for Disease Control (CDC) and World Health Organization (WHO) have deemed the COVID-19 virus a global pandemic of unprecedented severity in modern times. In 2019, this novel Coronavirus (COVID-19) emerged from the Asian continent and has now caused upwards of 1million deaths and over 6 million infections globally. Currently, the estimated global economic impact is over 5 Trillion dollars. Understanding the host response to pathogens, specifically the cellular and humoral responses, has played an important role in new non-antibiotic therapies. Bismuth subsalicylate (Pepto-Bismol) has a potential role in the clearance and/or recurrence of enteric viral infections.
Interventions
- DRUG Bismuth Subsalicylate 262 milligram (mg) Oral Tablet, Chewable
- OTHER Placebo oral tablet without BSS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2020-10-27 |
| Est. Completion | 2021-08-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04811339
The ClinicalTrials.gov registry entry for NCT04811339 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bismuth Subsalicylate 262 milligram (mg) Oral Tablet, Chewable is the first listed.
NCT04811339 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04811339 about?
NCT04811339 is a clinical study titled "Studies of COVID-19 Patients Treated With Oral Bismuth Subsalicylate (Pepto-Bismol)". The Center for Disease Control (CDC) and World Health Organization (WHO) have deemed the COVID-19 virus a global pandemic of unprecedented severity in modern times. In 2019, this novel Coronavirus (COVID-19) emerged from the Asian continent and has now caused upwards of 1million deaths and over 6 mi...
What is the current status of trial NCT04811339?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2020-10-27. Estimated completion is 2021-08-15.
What interventions are being tested in trial NCT04811339?
The interventions under investigation include: Bismuth Subsalicylate 262 milligram (mg) Oral Tablet, Chewable (DRUG), Placebo oral tablet without BSS (OTHER).
Who is sponsoring clinical trial NCT04811339?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.